Rheumatoid Arthritis and Immune Dynamics: A Survey

www.surveyx.cn

Abstract

This survey paper examines the intricate interplay of immune cell dynamics in rheumatoid arthritis (RA), focusing on the Th17/Treg balance and the potential of Traditional Chinese Medicine (TCM) in disease management. RA, a multifactorial autoimmune disorder, is characterized by chronic inflammation and joint damage, necessitating a comprehensive understanding of its pathogenesis. The paper explores the spatiotemporal dynamics of immune cells, highlighting the roles of chemokine signaling and dendritic cell subsets in modulating immune responses. Central to RA's pathology is the Th17/Treg balance, influenced by genetic, environmental, and metabolic factors. Disruptions in this balance exacerbate autoimmune responses, underscoring the need for targeted therapeutic interventions. TCM offers a holistic approach to RA, with syndrome differentiation providing insights into personalized treatment strategies. The integration of TCM with modern medical practices is discussed, emphasizing innovative applications and network pharmacology to enhance therapeutic efficacy. The paper also delves into inflammatory pathways, focusing on cytokine activity and the non-canonical NFB pathway as potential therapeutic targets. Current research highlights the benefits of combining TCM with conventional treatments, offering a synergistic approach to RA management. Future directions include refining predictive models, exploring gut microbiota's role, and advancing peptide-based therapies to restore immune balance. This multidisciplinary approach aims to develop novel therapeutic strategies, ultimately improving patient outcomes in RA.

1 Introduction

1.1 Significance of Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a multifactorial autoimmune disease with a considerable global impact, particularly in its seropositive form, affecting millions worldwide [1]. It primarily targets the synovial membrane, resulting in chronic inflammation and progressive joint destruction. The variability in clinical outcomes necessitates multinomial prediction models to enhance treatment strategies and improve patient prognosis [2]. Managing RA is further complicated by the need to detect treatment effects in scenarios with differing outcome distributions, especially in the tails, which is critical for optimizing therapeutic interventions [3]. Additionally, RA significantly impacts geriatric patients, where fibronectin influences orthopedic implant surgeries, affecting biofilm formation and increasing the risk of implant infections [4]. These complexities highlight the urgent need for improved diagnostic and therapeutic strategies to alleviate the disease's burden and enhance the quality of life for affected individuals.

1.2 Structure of the Survey

This survey provides a comprehensive overview of rheumatoid arthritis (RA) and its underlying immunological dynamics, focusing on the balance between Th17 and Treg cells and the role of



Figure 1: chapter structure

traditional Chinese medicine (TCM) in RA management. The first section introduces RA, emphasizing its significance as a chronic autoimmune disease and the importance of understanding immune cell dynamics. The background section explores key concepts such as the spatiotemporal dynamics of immune cells, Th17/Treg balance, and TCM syndrome types, establishing their relevance to RA. Subsequent sections investigate the mechanisms of immune cell migration, the influence of chemokine signaling and dendritic cell subsets, and the stages of RA progression. The survey also examines factors affecting the Th17/Treg balance and strategies for immune regulation in RA. A detailed analysis of TCM discusses its principles, practices, and potential efficacy in treating RA. Inflammatory pathways, including molecular mechanisms and the involvement of cytokines and the non-canonical NFB pathway, are thoroughly detailed. Finally, the integration of TCM with modern medical practices is considered, showcasing current research, innovative applications, and case studies. The conclusion synthesizes key insights and suggests future research directions, emphasizing the importance of a multidisciplinary approach in RA treatment.The following sections are organized as shown in Figure 1.

2 Background and Definitions

2.1 Rheumatoid Arthritis: Definition and Etiology

Rheumatoid arthritis (RA) is a chronic autoimmune disorder marked by persistent joint inflammation and systemic effects, leading to significant disability and joint destruction. Its etiology is multifaceted, involving genetic, environmental, and immunological factors. Genetic predisposition is shaped by both HLA and non-HLA variants, with single nucleotide polymorphisms (SNPs) elucidating the genetic basis of RA, although identifying significant high-order interactions among these SNPs remains challenging. Environmental factors, such as smoking and infections, can alter self-proteins, fostering

autoimmunity [5]. The composition of gut microbiota also plays a crucial role in inflammation, with variations leading to diverse inflammatory responses and disease outcomes [6].

Immunologically, RA is characterized by immune cell subset dysregulation, resulting in chronic inflammation and joint damage. Anti-citrullinated protein autoantibodies (ACPA) and anti-collagen II (CII) antibodies are key markers, with the latter contributing to pain mechanisms independent of inflammation [5]. The role of inducible nitric oxide synthase (iNOS) in immune cells adds complexity to disease progression [7]. Vascular morphology in RA highlights the interaction between immune dynamics and vascular structures, impacting disease outcomes [8]. An integrative approach combining demographic and genomic studies is essential for advancing predictive models and improving RA management [2]. Evaluating causal inference methods using large datasets, such as a cohort of approximately 120,000 RA patients, provides a comprehensive framework for understanding treatment effects, especially in scenarios where outcomes differ in the upper tail of the distribution.

2.2 Spatiotemporal Dynamics and Immune Balance

The spatiotemporal dynamics of immune cells are crucial in RA pathogenesis and progression, affecting both disease initiation and perpetuation. The migration and behavior of immune cells, including dendritic cells, T cells, and macrophages, are governed by chemotactic signals and mechanical cues, with the actin cytoskeleton facilitating these movements [9]. This enables immune cells to navigate synovial tissue, localizing at inflammation sites and contributing to RA's chronic inflammatory environment [7].

Dendritic cells are pivotal in activating and differentiating T cells, modulating the immune balance between pro-inflammatory Th17 cells and regulatory Treg cells [10]. Maintaining this equilibrium is vital for immune homeostasis within synovial joints; disruptions can lead to exacerbated inflammatory responses and accelerated disease progression. Characterizing immune cell migration stages—adhesion, crawling, and transmigration—provides foundational insights into cellular dynamics in RA [11].

Systemic analyses of immune cell motility in vivo have clarified these cells' responsiveness to various stimuli, elucidating their roles in RA progression [12]. Recent studies highlight the gut microbiota's potential influence on immune cell balance, suggesting that microbial dysbiosis and alterations in metabolites can affect the Th17/Treg equilibrium, as seen in other autoimmune conditions such as Myasthenia Gravis [13]. Understanding immune cell dynamics is crucial for unraveling RA pathophysiology and developing targeted therapeutic strategies to enhance patient outcomes. Causal inference models can further evaluate potential interventions on immune cell dynamics, particularly when randomized controlled trials are impractical [14].

2.3 Th17/Treg Balance in Autoimmunity

The balance between T helper type 17 (Th17) cells and regulatory T (Treg) cells is critical in autoimmune diseases, including RA. Th17 cells promote inflammation and autoimmunity, while Treg cells maintain immune homeostasis, preventing excessive immune responses. Disruptions in this balance can exacerbate autoimmune conditions, influencing disease progression and severity. Various factors—cytokine signaling, metabolic pathways, and intestinal microbiota—affect the Th17/Treg equilibrium, highlighting the complexity of immune regulation in autoimmune pathologies [15, 16, 17]. An imbalance favoring Th17 cells can lead to a loss of immune tolerance, exacerbating RA and contributing to other inflammatory conditions such as osteoporosis and metabolic diseases.

Microbial dysbiosis and altered bile acid metabolism significantly contribute to RA pathology by affecting the Th17/Treg balance [18]. Specific gut microbiota promote immune regulation and balance between Th17 and Treg cells, enhancing understanding of immune system modulation [19]. Genetic factors also play a crucial role in modulating this balance, and integrating genetic data with immune cell dynamics can provide deeper insights into RA pathophysiology, aiding predictions of individual variability in disease outcomes and therapeutic responses [20]. Additionally, the tumor microenvironment, influenced by gastric cancer stem cells, can impact the Th17/Treg balance, complicating immune responses [21].

The temporal dynamics of immune cell interactions are categorized into distinct stages—triggering, maturation, targeting, and fulminant—offering a framework for understanding RA progression and

other inflammatory diseases [20]. This framework underscores the significance of the Th17/Treg balance in dictating disease severity and outcomes.

Therapeutic interventions targeting the Th17/Treg balance show promise. Artesunate may modulate the balance of Th17 and Treg cells by affecting their proliferation and apoptosis, presenting a novel therapeutic approach for RA [22]. The cGAS–STING pathway has emerged as a promising target for modulating immune responses and re-establishing the Th17/Treg equilibrium, offering potential therapeutic avenues for autoimmune diseases [20]. Metabolic reprogramming is pivotal in the differentiation and balance of Th17 and Treg cells, emphasizing the importance of metabolic pathways in influencing T cell fate and function [23].

Understanding and modulating the Th17/Treg balance through genetic, microbial, and therapeutic approaches holds promise for improving disease management and patient outcomes. Further research into the underlying mechanisms and potential interventions will be essential for developing targeted therapies that can effectively restore immune homeostasis.

2.4 TCM Syndrome Types and Immune Cell Migration

Traditional Chinese Medicine (TCM) offers a unique perspective on RA by classifying the disease into various syndrome types, believed to influence immune cell migration and function. TCM syndromes are classified based on a holistic assessment of symptoms matched to specific patterns of disharmony in the body. Challenges in classification methods, such as latent class analysis (LCA), often lead to biased estimates due to unrealistic independence assumptions [24]. This necessitates more sophisticated models that accurately capture the complex relationships inherent in TCM diagnostics.

Interactions between TCM herbs and their effects on immune cell dynamics remain poorly understood, posing significant obstacles to quantifying and analyzing these interactions effectively [25]. Current models often lack interpretability and fail to incorporate core TCM theories, limiting their applicability in understanding how TCM syndrome types affect immune cell migration. Existing benchmarks in TCM primarily focus on basic knowledge, lacking the complexity required to evaluate diagnostic reasoning in syndrome differentiation [26].

The gut microbiome plays a crucial role in autoimmune diseases, including RA, influencing immune cell migration through bile acids and microbial metabolites [18]. This emphasizes the importance of integrating microbiome research insights into TCM practices, which traditionally emphasize the balance of internal and external health factors.

Future research should aim to quantify and automate the study of peptide strings and their implications for immune modulation, potentially providing new avenues for understanding TCM's impact on immune processes [27]. Generating a set of TCM herbs corresponding to treatment symptoms, while considering the complex relationships between symptoms and herbs, remains a challenging task that requires enhanced knowledge representation and reasoning capabilities [28].

3 Spatiotemporal Dynamics of Immune Cells in RA

Category	Feature	Method
Mechanisms of Immune Cell Migration	Statistical Analysis Models Advanced Imaging Techniques	HITS[29], MPM[2], COVES[3] NNSR-CEST[30]
Chemokine Signaling and DC Subsets	DC Migration Focus	AN[31]
Stages of RA Progression	Advanced Analytical Techniques Statistical Modeling	MB-MDR[32], ACDDI[33], UNet[34] OFCMM[35]

Table 1: This table provides a comprehensive overview of the various methods employed in studying the spatiotemporal dynamics of immune cells in rheumatoid arthritis (RA). It categorizes these methods into three main areas: mechanisms of immune cell migration, chemokine signaling and dendritic cell subsets, and the stages of RA progression. The table highlights the specific features and techniques used, including statistical models, advanced imaging methods, and analytical techniques, which are crucial for understanding and developing therapeutic interventions for RA.

In rheumatoid arthritis (RA), the spatiotemporal dynamics of immune cells are pivotal for understanding disease onset and progression. The complex interactions and migratory behaviors of immune cells highlight the intricate immune response mechanisms. Table 1 summarizes the advanced methods and

techniques utilized to explore the spatiotemporal dynamics of immune cells within the context of rheumatoid arthritis, providing insights into the mechanisms of immune cell migration, chemokine signaling, and stages of disease progression. Additionally, Table 2 provides a comprehensive summary of the advanced methods and techniques utilized to explore the spatiotemporal dynamics of immune cells within the context of rheumatoid arthritis. **??** illustrates the hierarchical structure of these dynamics, focusing on the mechanisms of immune cell migration, chemokine signaling, and the various stages of RA progression. This figure categorizes the modes and stages of immune cell migration, elucidates the role of chemokine signaling in dendritic cell subsets, and outlines the progression stages of RA. By highlighting significant research findings and advanced techniques used in the study of RA pathogenesis and therapeutic interventions, this section explores the mechanisms governing immune cell migration, their contribution to RA pathophysiology, and implications for therapeutic interventions.

3.1 Mechanisms of Immune Cell Migration

Understanding immune cell migration is essential for elucidating RA pathology, where precise orchestration of cell movement and localization is crucial for disease initiation and progression. Immune cell migration can be categorized into mesenchymal and amoeboid modes, each with distinct regulatory mechanisms. Mesenchymal migration involves elongated cell shapes and extracellular matrix degradation, while amoeboid migration features rounded cells moving through tissues without significant proteolytic activity [9].

The migration process includes signaling, polarization, and directional movement stages, regulated by complex signaling pathways. Chemokine signaling is vital in dendritic cells (DCs), affecting their migratory properties and immune functions, thereby influencing pro-inflammatory and regulatory immune responses [10]. The interaction stages with barriers like the blood-brain barrier involve capture, rolling, arrest, crawling, and diapedesis, with molecular interactions critical at each stage [36].

Metrics developed to quantify immune cell movement dynamics provide insights into their behavior under various conditions [12]. These metrics are crucial for assessing immune cell motility and responsiveness, integral to RA's chronic nature. Encoding networks and recurrent units capture long-term dependencies in immune responses, offering insights into RA's chronic and systemic nature [31].

Advanced imaging techniques, such as Neural Network-based Super-Resolution for CEST MRI, enhance visualization of small anatomical structures, aiding in studying immune cell movement and localization within synovial tissue [30]. Understanding these mechanisms is crucial for developing therapies that modulate immune cell migration, aiming to reduce RA's inflammatory environment. High-dimensional Individualized Treatment Selection methods provide accurate treatment effect inferences based on high-dimensional covariates, crucial for understanding immune dynamics in RA [29]. Multinomial prediction models assess immune cell migration dynamics, optimizing therapeutic strategies [2]. Statistical tests like COVES refine therapeutic approaches by detecting treatment effects through covariate-adjusted expected shortfalls [3].

Figure 2 illustrates the mechanisms of immune cell migration, categorizing them into migration modes, stages, and advanced techniques. This figure highlights mesenchymal and amoeboid migration modes, stages such as signaling and polarization, and advanced techniques including imaging and prediction models. These mechanisms are crucial in RA pathogenesis, where immune cells significantly contribute to inflammation and joint damage. By examining these dynamics, researchers aim to uncover therapeutic targets to mitigate RA's adverse effects by modulating immune cell migration and activity [10, 37, 38].

3.2 Chemokine Signaling and DC Subsets

Chemokine signaling is pivotal in orchestrating immune cell dynamics in RA. Dendritic cell (DC) migration and function are influenced by chemokine receptors, guiding them to inflammation sites and facilitating T cell interactions, thereby modulating immune responses [38]. Research has elucidated migratory mechanisms and pathways regulating DC functions, offering insights into their roles in immune modulation and RA pathogenesis [10].



Figure 2: This figure illustrates the mechanisms of immune cell migration, categorizing them into migration modes, stages, and advanced techniques. It highlights mesenchymal and amoeboid migration modes, stages such as signaling and polarization, and advanced techniques including imaging and prediction models.

Immune cell migration stages are organized by environmental dimensionality and guiding cues, such as chemical and mechanical signals [37]. Chemokine signaling guides DCs through chemotaxis, influencing actin-dependent movement, crucial for effective immune surveillance [9].

RNA-seq analysis has assessed immune responses in RA patients treated with abatacept, highlighting chemokine signaling's impact on immune cell dynamics [39]. Understanding transcriptional changes associated with chemokine receptor engagement informs targeted therapies aimed at modulating immune cell migration and function.

The Swiss Clinical Quality Management database, with extensive RA patient data, is a valuable resource for exploring chemokine signaling and DC subsets' interactions. This database facilitates analysis of therapy responses and biomarkers linked to disease progression and treatment efficacy [31].

3.3 Stages of RA Progression

RA progression is characterized by distinct stages reflecting dynamic immune cell behavior changes and joint pathology impacts. Initially, the preclinical stage is marked by autoantibodies like rheumatoid factor and anti-citrullinated protein antibodies, indicating an autoimmune response without clinical manifestation [35]. In the early symptomatic stage, immune cells infiltrate synovial joints, driven by chemotactic signals, leading to synovitis and swelling [40].

The targeting stage involves sustained immune cell infiltration and activation within synovial tissue, resulting in chronic inflammation and joint damage. This stage features activated T cells, B cells, and macrophages perpetuating tissue destruction [40]. Advanced imaging techniques, like NIR-II imaging, facilitate monitoring immune cell dynamics and bone integrity in animal models, providing insights into RA progression's temporal aspects [41].

In the chronic stage, inflammation becomes entrenched, leading to irreversible joint damage and deformities. Treatment response variability among patients with similar phenotypes underscores RA progression complexity and the need for personalized strategies [1]. Automated methods, such as the UNet segmentation algorithm, analyze imaging data effectively, enhancing research capabilities in understanding RA pathology [34].

Machine learning algorithms, like MB-MDR, predict individual RA trait progression, demonstrating improved predictive accuracy over traditional methods [32]. These approaches, alongside experimental models using EGC images, provide a comprehensive framework for evaluating RA progression stages and associated immune dynamics [33].

Understanding RA progression stages and corresponding immune cell dynamics is essential for developing targeted therapeutic interventions. These interventions aim to effectively modulate the disease course, enhance clinical outcomes, and address RA's diverse pathogenic mechanisms, including inflammation, joint damage, and systemic complications. By recognizing specific immune cell subsets involved at various RA stages, clinicians can implement early therapeutic strategies

aiming for clinical remission, preserving joint integrity, and improving patients' quality of life [40, 42, 43, 44].

Feature	Mechanisms of Immune Cell Migration	Chemokine Signaling and DC Subsets	Stages of RA Progression
Migration Mode	Mesenchymal, Amoeboid	Actin-dependent Movement	Chemotactic Signals
Signaling Mechanism	Chemokine Signaling	Chemokine Receptors	Autoantibodies
Imaging Technique	Super-Resolution Cest Mri	Not Specified	Nir-II Imaging

Table 2: This table provides a comparative overview of the methods used to study the spatiotemporal dynamics of immune cells in rheumatoid arthritis (RA). It highlights the migration modes, signaling mechanisms, and imaging techniques relevant to immune cell migration, chemokine signaling in dendritic cell subsets, and the stages of RA progression. The table serves to elucidate the complex interactions and advanced methodologies applied in RA research.

4 Th17/Treg Balance in Autoimmunity

4.1 Pathogenic Factors Influencing Th17/Treg Balance

The Th17/Treg balance plays a pivotal role in rheumatoid arthritis (RA) pathogenesis, influenced by genetic, environmental, and metabolic factors. Th17 cells primarily rely on glycolysis, whereas Treg cells depend on fatty acid oxidation, reflecting their distinct metabolic profiles that affect differentiation and function [23]. Genetic variability in RA necessitates personalized therapeutic approaches targeting specific pathogenic pathways [2]. The modulation of the Th17/Treg balance by gastric cancer stem cells (GCSCs) in the tumor microenvironment suggests parallels in autoimmune diseases like RA [21]. Environmental factors, such as high-salt diets promoting Th17 differentiation and dietary fibers enhancing Treg populations, significantly impact this balance [22]. Gut microbiota dysbiosis, linked to autoimmune diseases like Myasthenia Gravis, may similarly influence the Th17/Treg balance in RA [13].

Cytokines and inflammatory mediators are crucial in maintaining or disrupting this balance, with current treatments often failing to restore it, resulting in persistent inflammation and joint damage in RA [22]. The complexity of immune signaling pathways, including those involving LFA-1, further complicates the understanding of factors affecting this balance [3]. Addressing these pathogenic factors is essential for developing targeted interventions to restore immune homeostasis in RA.

Figure 3 illustrates the critical pathogenic factors influencing the Th17/Treg balance in rheumatoid arthritis, categorized into genetic and metabolic factors, environmental and microbial influences, and therapeutic implications. Each category includes specific examples and references that contribute to understanding and potentially modulating this balance. Research into genetic, microbial, and molecular mechanisms regulating Th17 and Treg cells is crucial for understanding gut microbiota and immune cell interactions in autoimmune disorders. This knowledge could inform targeted therapeutic strategies, such as fecal microbiota transplantation (FMT), aimed at restoring the Th17/Treg equilibrium, thereby improving outcomes in RA, multiple sclerosis, and inflammatory bowel disease [19, 45].

4.2 Immune Regulation and Modulation

Modulating the Th17/Treg balance is a promising therapeutic strategy for immune regulation in RA, crucial for determining disease outcomes and potentially enhancing patient prognosis [20]. Mesenchymal stem cells (MSCs) are significant candidates for immunomodulation due to their ability to secrete hepatocyte growth factor (HGF), facilitating the conversion of Th17 cells to Treg cells. This mechanism illustrates MSCs' potential in redirecting CD4+ T cell differentiation from a pro-inflammatory to an anti-inflammatory phenotype [46]. MSCs exert immunomodulatory effects through various pathways, including soluble factors, receptor-ligand interactions, extracellular vesicles, mitochondrial transfer, metabolic reprogramming, and autophagy, providing a comprehensive framework for their role in restoring the Th17/Treg balance in RA [47]. Targeting these pathways is crucial for therapeutic benefits, emphasizing the reciprocal relationship between Th17 and Treg cells [48].

The non-canonical NFB pathway offers a promising target for immune response modulation, warranting further exploration due to its significant role in various immune responses, potentially providing



Figure 3: This figure illustrates the critical pathogenic factors influencing the Th17/Treg balance in rheumatoid arthritis, categorized into genetic and metabolic factors, environmental and microbial influences, and therapeutic implications. Each category includes specific examples and references that contribute to understanding and potentially modulating this balance.

new insights into RA treatment strategies [23]. Inhibiting inflammatory cytokines, such as IL-6, has shown potential in restoring the balance between pro-inflammatory Th17 and anti-inflammatory Treg cells, suggesting benefits for improving insulin sensitivity and other metabolic outcomes [49]. Gut microbiota significantly influence the Th17/Treg balance, with specific microbes and metabolites acting as key modulators. Therapeutic approaches like fecal microbiota transplantation may alter gut microbiota composition, impacting immune regulation and offering novel treatment options for RA [13]. Current research highlights the efficacy of gut microbiota modulation in restoring immune balance in autoimmune conditions, indicating potential advancements in RA management.

Targeting the Th17/Treg balance through strategies including MSCs, cytokine inhibition, and gut microbiota modulation holds promise for achieving immune regulation in RA. Continued research into the differentiation and functional roles of various immune cell subsets, such as T cells, B cells, dendritic cells, monocytes, and macrophages, is essential for developing targeted therapies that effectively restore immune homeostasis. Understanding the complex interactions and signaling pathways of these immune cells, particularly in the context of rheumatoid arthritis and cancers, may lead to improved patient outcomes through innovative treatment strategies addressing underlying metabolic dysregulations [42, 43].

5 Traditional Chinese Medicine and RA

5.1 Traditional Chinese Medicine Perspective

Traditional Chinese Medicine (TCM) provides a holistic approach to rheumatoid arthritis (RA) by emphasizing the balance and harmony of bodily systems. The principle of syndrome differentiation allows for personalized treatments by synthesizing clinical information to identify disharmony patterns [50]. This aligns with modern statistical methods like the HITS method, which supports individualized therapeutic responses [29]. Network medicine has further clarified TCM's role in RA management, with frameworks linking herb targets to symptom-associated genes, illuminating TCM's therapeutic mechanisms [51]. The RoKEPG method, combining RoBERTa with knowledge enhancement, exemplifies TCM principles in prescription generation [28].

The integration of AI and large language models into TCM practices, as seen in the TCMBench framework, modernizes treatment effectiveness [52]. Furthermore, peptide strings as therapeutic models align with TCM's philosophy, suggesting innovative pathways for merging traditional and contemporary strategies [43]. TCM's emphasis on interstitial connective tissues in fluid transport offers new insights into RA pathophysiology [53]. Artesunate treatment, which induces apoptosis in Th17 cells while promoting Treg cell proliferation, highlights TCM's potential to correct immune imbalances in RA [22].

As illustrated in Figure 4, the integration of Traditional Chinese Medicine (TCM) in managing rheumatoid arthritis underscores its holistic approach, modern integration with AI and peptide therapies, and therapeutic strategies such as artesunate treatment and acupuncture. By integrating

traditional theories with contemporary scientific advancements, TCM provides a robust framework for innovative therapeutic strategies addressing RA's complex pathophysiology. This approach incorporates practices such as acupuncture and herbal medicine, aligning with methodologies like network pharmacology and intelligent medicine, enhancing disease understanding and clinical outcomes. Collaboration between TCM practitioners and Western healthcare professionals, supported by standardized data and evidence-based research, promotes a comprehensive understanding of RA treatment options [54, 55, 56, 57, 51].



Figure 4: This figure illustrates the integration of Traditional Chinese Medicine (TCM) in managing rheumatoid arthritis, highlighting its holistic approach, modern integration with AI and peptide therapies, and therapeutic strategies such as artesunate treatment and acupuncture.

5.2 TCM Practices and Their Efficacy in RA Treatment

The efficacy of Traditional Chinese Medicine (TCM) in treating rheumatoid arthritis (RA) is increasingly recognized, particularly through integrating traditional methodologies with modern scientific approaches. Intelligent systems using large language models have advanced disease classification, syndrome identification, and herbal medicine recommendations, enhancing TCM interventions' precision and effectiveness [58]. These systems utilize TCM-specific datasets, fostering a nuanced understanding of its therapeutic potential.

TCM's efficacy is highlighted through systematic exploration of symptom-prescription pairs, as shown by studies using the TCM Prescription Knowledge Base, which improve understanding of symptom-herb relationships [59]. The RoKEPG method's knowledge enhancement techniques significantly improve prescription generation accuracy, aiding TCM practitioners [28]. Network pharmacology is crucial in elucidating TCM's therapeutic mechanisms, predicting herb effectiveness against RA symptoms and identifying novel herb-symptom pairs [51].

Acupuncture, a key TCM component, has proven more effective than Chinese herbal and Western medicine in certain contexts, with combination therapies often yielding the most significant benefits [53]. Investigating acupoint-originated interstitial fluid pathways provides insights into TCM's circulatory systems, elucidating acupuncture's influence on systemic health and RA symptoms. Incremental causal effect estimation applied to real-world data evaluates TCM practices' efficacy in RA management, supporting discussions on alternative and complementary approaches to conventional therapies [60].

5.3 Network Pharmacology and TCM

Network pharmacology offers a comprehensive framework for understanding Traditional Chinese Medicine's (TCM) therapeutic effects on rheumatoid arthritis (RA) by examining complex interactions among herbs, symptoms, and biological pathways. Gan et al. illustrate this approach through a framework analyzing herb-symptom relations across the interactome, providing a holistic perspective that transcends single herbs or prescriptions [51]. Integrating network medicine with TCM deepens understanding of TCM formulations' impact on RA pathology.

Innovative methodologies like RoKEPG enhance network pharmacology by combining RoBERTa model pre-training with TCM knowledge, using an attention mask matrix to unravel complex TCM interactions and their effects on RA [28]. The TCMBench framework introduces the TCMScore

metric, assessing response quality based on TCM semantics and knowledge consistency, addressing traditional metric limitations and ensuring accurate interpretations of TCM's therapeutic potential [52].

The Human Interstitial Fluid Connectome Atlas (HIFCA) proposed by Hongyi et al. describes anatomical structures related to acupoint-originated interstitial fluid circulation, providing insights into TCM practices like acupuncture [53]. This anatomical understanding complements network pharmacology by elucidating TCM interventions' physiological underpinnings. The THCluster framework enhances herb categorization by integrating multiple entities, improving TCM prescriptions' accuracy and efficacy [61].

Network pharmacology elucidates intricate interactions in TCM formulations, offering fresh insights into their therapeutic effects on RA. Advancements in data management, standardization, and computational methodologies integration are crucial for unlocking TCM's potential in contemporary medical practices. These improvements enhance clinical decision-making, facilitate drug discovery, and support systematic understanding of complex diseases like RA through network pharmacology. By effectively organizing and utilizing expanding clinical and research data, TCM can significantly improve RA treatment outcomes, leading to more personalized and effective therapeutic strategies [56, 57].

6 Inflammatory Pathways in RA

6.1 Molecular Mechanisms Driving Inflammation

Rheumatoid arthritis (RA) involves complex inflammatory mechanisms driven by genetic, biochemical, and cellular factors. Central to RA pathogenesis is the dysregulation of immune cell functions, notably the imbalance between Th17 and Treg cells, which exacerbates disease progression. Mitochondrial dysfunction contributes to this imbalance by releasing damage-associated molecular patterns (DAMPs), triggering inflammatory responses and enhancing disease activity through immunogenic neo-epitopes and autoreactive B cell activation [62, 63, 1]. The NLRP3 inflammasome, regulated by posttranslational modifications and protein interactions, plays a pivotal role by producing pro-inflammatory cytokines like IL-1 [64]. Key signaling pathways such as NF-B, MAPK, and JAK-STAT are crucial in inflammation regulation and serve as promising therapeutic targets [65].

The actomyosin cytoskeleton, crucial for immune cell migration and target detection, involves adhesion molecules like LFA-1, making them potential therapeutic targets in autoimmune diseases like RA [9, 11]. Modulating inducible nitric oxide synthase (iNOS) also presents therapeutic potential due to its role in immune response regulation [7]. Advanced imaging techniques, particularly those utilizing neural networks, enhance visualization of RA's molecular and cellular mechanisms, surpassing traditional methods [41]. The gut microbiome's role in RA, with specific microbes linked to inflammation, suggests potential therapeutic interventions via prebiotics and probiotics [6].

Integrating network pharmacology with Traditional Chinese Medicine (TCM) offers a holistic approach to understanding and modulating RA's inflammatory pathways, emphasizing complex biological data integration for identifying therapeutic targets and enhancing comprehension of RA's molecular mechanisms [66]. As illustrated in Figure 5, the hierarchical structure of rheumatoid arthritis inflammation mechanisms categorizes immune dysregulation, signaling pathways, and therapeutic targets as key areas of focus. Continued research into these pathways is crucial for developing targeted therapies that effectively manage inflammation and improve patient outcomes in RA.

6.2 Cytokine Storm and Inflammatory Cytokines

Cytokines are pivotal in rheumatoid arthritis (RA) pathogenesis, acting as key mediators of inflammation. Interleukin-6 (IL-6) is particularly instrumental in sustaining chronic inflammation in RA. Dysregulated dendritic cell (DC) migration exacerbates cytokine production, contributing to immune pathologies [10]. The NLRP3 inflammasome further intensifies RA's inflammatory environment by releasing pro-inflammatory cytokines [64]. The cytokine storm, akin to conditions like COVID-19, exemplifies the potential for excessive cytokine release to cause systemic inflammation and tissue damage [39]. This highlights the need for targeted therapies to modulate cytokine activity [65]. The



Figure 5: This figure illustrates the hierarchical structure of rheumatoid arthritis inflammation mechanisms, categorizing immune dysregulation, signaling pathways, and therapeutic targets as key areas of focus.

variability in compound bioavailability, such as flavonoids, poses challenges in developing effective interventions [67].

Mitochondrial DAMPs and pathways like cGAS-STING1 are crucial in cytokine regulation and RA's inflammatory response [63]. The non-canonical NFB pathway, with its complex receptor activation and downstream effects, remains a potential therapeutic target [68]. Understanding these intricate signaling networks is essential for devising strategies to control cytokine-driven inflammation in RA and improve patient outcomes.

6.3 Non-canonical NFB Pathway

The non-canonical NFB pathway significantly influences rheumatoid arthritis (RA) pathogenesis by contributing to immune response dysregulation and chronic inflammation. This pathway, distinct from the canonical NFB pathway, is activated through specific receptors and involves processing the NFB2 precursor protein, p100, into the active p52 subunit, which translocates to the nucleus to regulate gene expression [68]. Dysregulation of this pathway is linked to immune deficiencies and inflammatory diseases, underscoring its role in immune homeostasis [68].

In RA, the non-canonical NFB pathway perpetuates synovial inflammation by persistently activating immune cells and producing pro-inflammatory cytokines. It also regulates lymphoid organ development and adaptive immune responses, suggesting its potential as a therapeutic target for modulating immune activity in RA. However, the molecular mechanisms and receptor interactions within this pathway require further exploration to clarify their impact on RA pathogenesis [68].

Mitochondrial dysfunction's association with inflammatory pathway activation, including the non-canonical NFB pathway, provides insights into the interplay between cellular metabolism and immune regulation in RA [63]. Integrin LFA-1, involved in immune cell adhesion and signaling, interacts with NFB-related pathways, though its mechanosensing capabilities and full signaling pathways are not fully understood, necessitating further investigation [11].

The non-canonical NFB pathway is pivotal in RA's inflammatory processes, mediating immune functions and autoimmune disease pathogenesis. Dysregulation of this pathway contributes to RA onset and progression by mediating inflammatory responses and influencing genetic and environmental interactions that initiate the disease [68, 69, 1]. Continued exploration of its regulatory mechanisms and interactions with other cellular pathways is essential for developing targeted interventions aimed at restoring immune balance and alleviating chronic inflammation in RA.

7 Integration of TCM and Modern Medicine

7.1 Current Research and Integration Strategies

The integration of Traditional Chinese Medicine (TCM) with modern medical practices in rheumatoid arthritis (RA) treatment is increasingly recognized for its potential benefits. Network medicine frameworks, such as those developed by Gan et al., analyze herb-chemical-target relationships to

provide a systematic understanding of TCM's biological interactions [51]. Advances in network pharmacology have identified novel herb-symptom pairs, facilitating comprehensive treatment strategies that combine TCM modalities with biomedical interventions. This multidisciplinary approach aims to enhance RA symptom management and patient outcomes through personalized healthcare frameworks. Ongoing research into TCM's mechanistic foundations is expected to provide scientific validation, further facilitating its integration into mainstream healthcare [54, 56, 28, 57].

Machine learning techniques, such as the RoKEPG method, demonstrate AI's transformative potential in integrating TCM and modern medicine. Utilizing a pre-trained RoBERTa model incorporating TCM knowledge, RoKEPG enhances clinical decision-making by addressing complex nonlinear relationships between symptoms and prescriptions, improving diagnosis and treatment [28, 55, 70]. By integrating TCM knowledge into computational models, researchers can predict the efficacy of combined treatment approaches and optimize therapeutic regimens.

The integration of TCM and modern medicine leverages TCM's holistic principles and network pharmacology to elucidate interactions between herbal therapies and disease mechanisms. Recent advancements in TCM network pharmacology, combining computational, experimental, and clinical methodologies, aim to clarify RA's biological foundations for more effective treatment strategies. Establishing standardized research processes will support TCM's development within contemporary healthcare systems [54, 56, 57]. Continued research on herb-chemical-target relations is essential for addressing RA's complex pathophysiology.

7.2 Innovative Medical Applications

Innovative applications integrating TCM with modern medical technologies are advancing RA therapeutic strategies. Network pharmacology provides a framework for understanding TCM herbs' interactions with modern pharmaceuticals, identifying synergistic effects that enhance efficacy and minimize side effects [51]. Advanced computational models simulate pharmacokinetic and pharmacodynamic interactions of TCM formulations with modern drugs, utilizing large datasets and machine learning to predict treatment outcomes and enable personalized medicine approaches [28].

Integrating TCM with imaging technologies, such as neural network-based super-resolution MRI, enhances monitoring of disease progression and treatment responses, allowing real-time visualization of combined therapies' effects on joint inflammation [41]. AI applications in TCM, exemplified by platforms like TCMBench, refine TCM practices by incorporating modern scientific methodologies, enhancing diagnosis and treatment precision [52].

The integration of TCM with modern medical technologies signifies a transformative advancement in RA treatment, combining TCM's holistic principles with contemporary biomedical methods. Innovative research methodologies like network pharmacology aim to enhance understanding of disease mechanisms and improve patient outcomes, bridging traditional and modern medical paradigms for more effective, individualized treatment solutions [54, 55, 56, 57]. Continued exploration of these applications is crucial for unlocking the full potential of combined therapies, ultimately improving RA patients' quality of life.

7.3 Case Studies and Evidence of Successful Integration

The integration of TCM with modern medical practices in RA treatment has shown promising results, as evidenced by various case studies and clinical trials. These studies demonstrate the synergistic benefits of combining TCM formulations with conventional therapies, enhancing therapeutic efficacy and improving patient outcomes. Integrative strategies leverage TCM's unique mechanisms, such as acupuncture and herbal medicine, to effectively address complex diseases, fostering collaboration between TCM practitioners and conventional healthcare providers [54, 57].

A notable case study investigated acupuncture alongside standard pharmacological treatments for RA, showing that combined therapy significantly reduced pain and inflammation compared to conventional treatment alone. Acupuncture enhanced anti-inflammatory drug effects through cytokine modulation and improved joint microcirculation [51]. Another study explored TCM herbal formulations with DMARDs, where patients reported better symptom control and reduced flare-up frequency. Herbal formulations were tailored to individual needs based on TCM diagnostics [28].

Additionally, a clinical trial examined TCM dietary interventions alongside standard RA treatments. Patients adhering to a TCM-inspired diet showed improved joint function and reduced inflammation, highlighting dietary modifications' potential to complement pharmacological interventions [52]. Network pharmacology studies support TCM and modern medicine integration, identifying herb-drug interactions that enhance therapeutic effects while minimizing adverse reactions [51].

The comprehensive analysis of case studies and clinical trials underscores the significant advantages of integrating TCM with contemporary medical practices in managing RA. These studies illuminate TCM's unique therapeutic approaches, such as acupuncture, herbal medicine, and dietary interventions, which complement and enhance modern treatments' efficacy. Advances in TCM research methodologies, including network pharmacology and rigorous clinical trial designs, provide a robust scientific foundation for this integration, facilitating improved patient outcomes and fostering a more holistic healthcare model [54, 56, 26, 57]. Continued research and collaboration between TCM practitioners and modern healthcare providers will be essential for optimizing treatment strategies and enhancing patient outcomes.

8 Conclusion

8.1 Research Gaps and Future Directions

Rheumatoid arthritis (RA) poses intricate challenges that demand comprehensive research to improve disease management. A key area requiring attention is the refinement of variable selection techniques for multinomial prediction models (MPMs), which are essential for accurately predicting RA outcomes. Future research should emphasize the use of fractional polynomials and the establishment of robust sample size criteria for external validation to enhance predictive model accuracy.

The exploration of gut microbiota's role in RA pathogenesis offers promising research potential. Identifying specific probiotics or dietary interventions that can restore gut microbiota balance may not only improve RA outcomes but also benefit other autoimmune diseases. Additionally, the therapeutic potential of modulating T cell metabolic responses through small molecule inhibitors targeting specific pathways presents a novel avenue for RA treatment development.

In the realm of diagnostics, optimizing the selection of quantile and extending methodologies to address significant tail differences could improve the detection of treatment effects in RA. Enhancing computational efficiency and adapting trial designs to incorporate early response outcomes are also crucial for improving decision-making in clinical trials.

The integration of Traditional Chinese Medicine (TCM) with modern scientific methods presents another promising research direction. Understanding the interactions between TCM and gut microbiota, along with elucidating the biological mechanisms underlying TCM syndromes, could lead to innovative therapeutic strategies. Additionally, optimizing artesunate dosing regimens and investigating its mechanisms of action through clinical trials could provide insights into its efficacy for RA patients.

From a technological perspective, refining evaluation metrics and expanding toolkits to include a broader range of causal inference methods are essential for advancing RA research. The development of peptide-based therapies aimed at restoring the balance between pro-inflammatory and anti-inflammatory signals also holds significant promise.

Addressing these research gaps through multidisciplinary approaches is crucial for developing innovative therapeutic strategies and improving patient outcomes in RA. Future studies should prioritize the integration of diverse data types, conduct real-world clinical evaluations, and explore additional prompting techniques to enhance model adaptability in RA treatments.

References

[1] Ellen M Gravallese and Gary S Firestein. Rheumatoid arthritis—common origins, divergent mechanisms. *New England Journal of Medicine*, 388(6):529–542, 2023.

[2] Celina K Gehringer, Glen P Martin, Ben Van Calster, Kimme L Hyrich, Suzanne M M Verstappen, and Jamie C Sergeant. How to develop, externally validate, and update multinomial prediction models, 2023.

[3] Xuming He, Ya-Hui Hsu, and Mingxiu Hu. Detection of treatment effects by covariate-adjusted expected shortfall, 2011.

[4] S Dutta Sinha, P. K. Maiti, and S Tarafdar. Vulnerability of geriatric patients to biomaterial associated infections: in vitro study of biofilm formation by pseudomonas aeruginosa on orthopedic implants, 2015.

[5] Molei Liu, Yi Zhang, Katherine P Liao, and Tianxi Cai. Augmented transfer regression learning with semi-non-parametric nuisance models, 2022.

[6] Zahraa Al Bander, Marloes Dekker Nitert, Aya Mousa, and Negar Naderpoor. The gut microbiota and inflammation: an overview. *International journal of environmental research and public health*, 17(20):7618, 2020.

[7] Qingjie Xue, Yingchun Yan, Ruihua Zhang, and Huabao Xiong. Regulation of inos on immune cells and its role in diseases. *International journal of molecular sciences*, 19(12):3805, 2018.

[8] John T. Nardini, Bernadette J. Stolz, Kevin B. Flores, Heather A. Harrington, and Helen M. Byrne. Topological data analysis distinguishes parameter regimes in the anderson-chaplain model of angiogenesis, 2021.

[9] Hélène D Moreau, Matthieu Piel, Raphaël Voituriez, and Ana-Maria Lennon-Duménil. Integrating physical and molecular insights on immune cell migration. *Trends in immunology*, 39(8):632–643, 2018.

[10] Juan Liu, Xiaomin Zhang, Yujie Cheng, and Xuetao Cao. Dendritic cell migration in inflammation and immunity. *Cellular & molecular immunology*, 18(11):2461–2471, 2021.

[11] Brandon L Walling and Minsoo Kim. Lfa-1 in t cell migration and differentiation. *Frontiers in immunology*, 9:952, 2018.

[12] Diego Ulisse Pizzagalli, Pau Carrillo-Barbera, Elisa Palladino, Kevin Ceni, Benedikt Thelen, Alain Pulfer, Enrico Moscatello, Raffaella Fiamma Cabini, Johannes Textor, Inge MN Wortel, et al. Systematic analysis of immune cell motility leveraging immunemap, an open intravital microscopy atlas. *bioRxiv*, pages 2024–12, 2024.

[13] Pan Chen and Xiangqi Tang. Gut microbiota as regulators of th17/treg balance in patients with myasthenia gravis. *Frontiers in immunology*, 12:803101, 2021.

[14] Yishai Shimoni, Ehud Karavani, Sivan Ravid, Peter Bak, Tan Hung Ng, Sharon Hensley Alford, Denise Meade, and Yaara Goldschmidt. An evaluation toolkit to guide model selection and cohort definition in causal inference, 2019.

[15] Rony Thomas, Sai Qiao, and Xi Yang. Th17/treg imbalance: implications in lung inflammatory diseases. *International Journal of Molecular Sciences*, 24(5):4865, 2023.

[16] Lei Zhu, Fei Hua, Wenge Ding, Kai Ding, Yige Zhang, and Chenyang Xu. The correlation between the th17/treg cell balance and bone health. *Immunity & Ageing*, 17(1):30, 2020.

[17] Gap Ryol Lee. The balance of th17 versus treg cells in autoimmunity. *International journal of molecular sciences*, 19(3):730, 2018.

[18] Xiuli Su, Xiaona Li, Yanqin Bian, Qing Ren, Leiguang Li, Xiaohao Wu, Hemi Luan, Bing He, Xiaojuan He, Hui Feng, Xingye Cheng, Pan-Jun Kim, Leihan Tang, Aiping Lu, Lianbo Xiao, Liang Tian, Zhu Yang, and Zongwei Cai. Microbiome-derived bile acids contribute to elevated antigenic response and bone erosion in rheumatoid arthritis, 2023.

[19] Hongyu Cheng, Xiong Guan, Dekun Chen, and Wentao Ma. The th17/treg cell balance: a gut microbiota-modulated story. *Microorganisms*, 7(12):583, 2019.

[20] Siwen Zhang, Xiaokun Gang, Shuo Yang, Mengzhao Cui, Lin Sun, Zhuo Li, and Guixia Wang. The alterations in and the role of the th17/treg balance in metabolic diseases. *Frontiers in Immunology*, 12:678355, 2021.

[21] Gastric cancer stem cells effect.

[22] Jia Liu, Xuezhi Hong, Dong Lin, Xiaohong Luo, Mengya Zhu, and Hanyou Mo. Artesunate influences th17/treg lymphocyte balance by modulating treg apoptosis and th17 proliferation in a murine model of rheumatoid arthritis. *Experimental and Therapeutic Medicine*, 13(5):2267–2273, 2017.

[23] Licheng Sun, Jinrong Fu, and Yufeng Zhou. Metabolism controls the balance of th17/t-regulatory cells. *Frontiers in immunology*, 8:1632, 2017.

[24] Nevin L. Zhang, Chen Fu, Teng Fei Liu, Bao Xin Chen, Kin Man Poon, Pei Xian Chen, and Yun Ling Zhang. A data-driven method for syndrome type identification and classification in traditional chinese medicine, 2016.

[25] Jingqi Zeng and Xiaobin Jia. Graph neural networks for quantifying compatibility mechanisms in traditional chinese medicine, 2024.

[26] Peng Xu, Hongjin Wu, Jinle Wang, Rongjia Lin, and Liwei Tan. Traditional chinese medicine case analysis system for high-level semantic abstraction: Optimized with prompt and rag, 2024.

[27] Razvan Tudor Radulescu. Across and beyond the cell are peptide strings, 2007.

[28] Hua Pu, Jiacong Mi, Shan Lu, and Jieyue He. Rokepg: Roberta and knowledge enhancement for prescription generation of traditional chinese medicine, 2023.

[29] Tianxi Cai, Tony Cai, and Zijian Guo. Optimal statistical inference for individualized treatment effects in high-dimensional models, 2020.

[30] Lukas Folle, Katharian Tkotz, Fasil Gadjimuradov, Lorenz Kapsner, Moritz Fabian, Sebastian Bickelhaupt, David Simon, Arnd Kleyer, Gerhard Krönke, Moritz Zaiß, Armin Nagel, and Andreas Maier. Towards super-resolution cest mri for visualization of small structures, 2021.

[31] Maria Hügle, Gabriel Kalweit, Thomas Huegle, and Joschka Boedecker. A dynamic deep neural network for multimodal clinical data analysis, 2020.

[32] Damian Gola and Inke R. König. Empowering individual trait prediction using interactions, 2019.

[33] Gustavo Z. Felipe, Jacqueline N. Zanoni, Camila C. Sehaber-Sierakowski, Gleison D. P. Bossolani, Sara R. G. Souza, Franklin C. Flores, Luiz E. S. Oliveira, Rodolfo M. Pereira, and Yandre M. G. Costa. Automatic chronic degenerative diseases identification using enteric nervous system images, 2020.

[34] Amaya Gallagher-Syed, Abbas Khan, Felice Rivellese, Costantino Pitzalis, Myles J. Lewis, Gregory Slabaugh, and Michael R. Barnes. Automated segmentation of rheumatoid arthritis immunohistochemistry stained synovial tissue, 2023.

[35] Aristidis K. Nikoloulopoulos. An one-factor copula mixed model for joint meta-analysis of multiple diagnostic tests, 2021.

[36] Luca Marchetti and Britta Engelhardt. Immune cell trafficking across the blood-brain barrier in the absence and presence of neuroinflammation. *Vascular Biology*, 2(1):H1–H18, 2020.

[37] Doriane Vesperini, Galia Montalvo, Bin Qu, and Franziska Lautenschläger. Characterization of immune cell migration using microfabrication. *Biophysical reviews*, 13:185–202, 2021.

[38] Henry R Hampton and Tatyana Chtanova. Lymphatic migration of immune cells. *Frontiers in immunology*, 10:1168, 2019.

[39] Antonio Julià, Irene Bonafonte, Antonio Gómez, María López-Lasanta, Mireia López-Corbeto, Sergio H. Martínez-Mateu, Jordi Lladós, Iván Rodríguez-Nunez, Richard M. Myers, and Sara Marsal. Blocking of the cd80/86 axis as a therapeutic approach to prevent progression to more severe forms of covid-19, 2020.

[40] Qiang Guo, Yuxiang Wang, Dan Xu, Johannes Nossent, Nathan J Pavlos, and Jiake Xu. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. *Bone research*, 6(1):15, 2018.

[41] Chao Mi, Xun Zhang, Chengyu Yang, Jianqun Wu, Xinxin Chen, Chenguang Ma, Sitong Wu, Zhichao Yang, Pengzhen Qiao, Yang Liu, Weijie Wu, Zhiyong Guo, Jiayan Liao, Jiajia Zhou, Ming Guan, Chao Liang, Chao Liu, and Dayong Jin. Nanoparticles passive targeting allows optical imaging of bone diseases, 2023.

[42] Pu Fang, Xinyuan Li, Jin Dai, Lauren Cole, Javier Andres Camacho, Yuling Zhang, Yong Ji, Jingfeng Wang, Xiao-Feng Yang, and Hong Wang. Immune cell subset differentiation and tissue inflammation. *Journal of hematology & oncology*, 11:1–22, 2018.

[43] Razvan Tudor Radulescu. Peptide strings clues to the genesis and treatment of rheumatoid arthritis: rebuilding self-protective immunity amid fungal ruins, 2008.

[44] Review/cme article.

[45] Patrizia Fasching, Martin Stradner, Winfried Graninger, Christian Dejaco, and Johannes Fessler. Therapeutic potential of targeting the th17/treg axis in autoimmune disorders. *Molecules*, 22(1):134, 2017.

[46] Qi-Hong Chen, Fei Wu, Lei Liu, Han-bing Chen, Rui-Qiang Zheng, Hua-Ling Wang, and Li-Na Yu. Mesenchymal stem cells regulate the th17/treg cell balance partly through hepatocyte growth factor in vitro. *Stem cell research & therapy*, 11:1–11, 2020.

[47] Huiru Hu, Hui Li, Ruoyu Li, Peidong Liu, and Hongbo Liu. Re-establishing immune tolerance in multiple sclerosis: focusing on novel mechanisms of mesenchymal stem cell regulation of th17/treg balance. *Journal of Translational Medicine*, 22(1):663, 2024.

[48] Hannah K Drescher, Lea M Bartsch, Sabine Weiskirchen, and Ralf Weiskirchen. Intrahepatic th17/treg cells in homeostasis and disease—it's all about the balance. *Frontiers in Pharmacology*, 11:588436, 2020.

[49] Limin Tao, Huanbing Liu, and Yanfeng Gong. Role and mechanism of the th17/treg cell balance in the development and progression of insulin resistance. *Molecular and Cellular Biochemistry*, 459:183–188, 2019.

[50] Yuanyuan Jin, Wei Zhang, Xiangnan He, Xinyu Wang, and Xiaoling Wang. Syndrome-aware herb recommendation with multi-graph convolution network, 2020.

[51] Xiao Gan, Zixin Shu, Xinyan Wang, Dengying Yan, Jun Li, Shany ofaim, Réka Albert, Xiaodong Li, Baoyan Liu, Xuezhong Zhou, and Albert-László Barabási. Network medicine framework reveals generic herb-symptom effectiveness of traditional chinese medicine, 2022.

[52] Wenjing Yue, Xiaoling Wang, Wei Zhu, Ming Guan, Huanran Zheng, Pengfei Wang, Changzhi Sun, and Xin Ma. Tcmbench: A comprehensive benchmark for evaluating large language models in traditional chinese medicine, 2024.

[53] Li Hongyi, Yin Yajun, Hu Jun, Li Hua, Wang Fang, Ji Fusui, and Ma Chao. An insight into acupoints and meridians in human body based on interstitial fluid circulation, 2020.

[54] Luís Carlos Matos, Jorge Pereira Machado, Fernando Jorge Monteiro, and Henry Johannes Greten. Understanding traditional chinese medicine therapeutics: an overview of the basics and clinical applications. In *Healthcare*, volume 9, page 257. MDPI, 2021.

[55] Yu-yu Duan, Peng-ran Liu, Tong-tong Huo, Song-xiang Liu, Song Ye, and Zhe-wei Ye. Application and development of intelligent medicine in traditional chinese medicine. *Current medical science*, 41(6):1116–1122, 2021.

[56] Wing-Kit Sunny Lam, Tony Sahama, and Randike Gajanayake. Constructing a traditional chinese medicine data warehouse application, 2016.

[57] WANG Xin, WANG Zi-Yi, Jia-Hui Zheng, and LI Shao. Tcm network pharmacology: a new trend towards combining computational, experimental and clinical approaches. *Chinese journal of natural medicines*, 19(1):1–11, 2021.

[58] Yirui Chen, Qinyu Xiao, Jia Yi, Jing Chen, and Mengyang Wang. Intelligent understanding of large language models in traditional chinese medicine based on prompt engineering framework, 2024.

[59] Wei Li, Zheng Yang, and Xu Sun. Exploration on generating traditional chinese medicine prescription from symptoms with an end-to-end method, 2018.

[60] Andrew Ying, Zhichen Zhao, and Ronghui Xu. Incremental causal effect for time to treatment initialization, 2024.

[61] Chunyang Ruan, Ye Wang, Yanchun Zhang, Jiangang Ma, Huijuan Chen, Uwe Aickelin, Shanfeng Zhu, and Ting Zhang. Thcluster: herb supplements categorization for precision traditional chinese medicine, 2020.

[62] Caroline Gronwall, Khaled Amara, Uta Hardt, Akilan Krishnamurthy, Johanna Steen, Marianne Engstrom, Meng Sun, A. Jimmy Ytterberg, Roman A. Zubarev, Dagmar Scheel-Toellner, Jeffrey D. Greenberg, Lars Klareskog, Anca I. Catrina, Vivianne Malmstrom, and Gregg J. Silverman. Autoreactivity to malondialdehyde-modifications in rheumatoid arthritis is linked to disease activity and synovial pathogenesis, 2017.

[63] Saverio Marchi, Emma Guilbaud, Stephen WG Tait, Takahiro Yamazaki, and Lorenzo Galluzzi. Mitochondrial control of inflammation. *Nature Reviews Immunology*, 23(3):159–173, 2023.

[64] Seungwha Paik, Jin Kyung Kim, Prashanta Silwal, Chihiro Sasakawa, and Eun-Kyeong Jo. An update on the regulatory mechanisms of nlrp3 inflammasome activation. *Cellular & molecular immunology*, 18(5):1141–1160, 2021.

[65] Linlin Chen, Huidan Deng, Hengmin Cui, Jing Fang, Zhicai Zuo, Junliang Deng, Yinglun Li, Xun Wang, and Ling Zhao. Inflammatory responses and inflammation-associated diseases in organs. *Oncotarget*, 9(6):7204, 2017.

[66] Runzhi Zhang, Xue Zhu, Hong Bai, and Kang Ning. Network pharmacology databases for traditional chinese medicine: review and assessment. *Frontiers in pharmacology*, 10:123, 2019.

[67] Jameel M Al-Khayri, Gandasi Ravikumar Sahana, Praveen Nagella, Biljo V Joseph, Fatima M Alessa, and Muneera Q Al-Mssallem. Flavonoids as potential anti-inflammatory molecules: A review. *Molecules*, 27(9):2901, 2022.

[68] Shao-Cong Sun. The non-canonical nf-κb pathway in immunity and inflammation. *Nature reviews immunology*, 17(9):545–558, 2017.

[69] Mihai G Netea, Frances Balkwill, Michel Chonchol, Fabio Cominelli, Marc Y Donath, Evangelos J Giamarellos-Bourboulis, Douglas Golenbock, Mark S Gresnigt, Michael T Heneka, Hal M Hoffman, et al. A guiding map for inflammation. *Nature immunology*, 18(8):826–831, 2017.

[70] Li Yizhen, Huang Shaohan, Qi Jiaxing, Quan Lei, Han Dongran, and Luan Zhongzhi. Exploring the comprehension of chatgpt in traditional chinese medicine knowledge, 2024.

Disclaimer:

SurveyX is an AI-powered system designed to automate the generation of surveys. While it aims to produce high-quality, coherent, and comprehensive surveys with accurate citations, the final output is derived from the AI's synthesis of pre-processed materials, which may contain limitations or inaccuracies. As such, the generated content should not be used for academic publication or formal submissions and must be independently reviewed and verified. The developers of SurveyX do not assume responsibility for any errors or consequences arising from the use of the generated surveys.